Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The US government just placed its first order for cefiderocol (Fetroja), a next-generation antibiotic, as part of national biosecurity preparedness. BARDA's Project BioShield spent $36.9 million on the drug, which targets hard-to-treat gram-negative bacterial infections. The purchase is part of a broader contract worth up to $482 million with Japanese drugmaker Shionogi.
The US government is bolstering its biodefense arsenal with a powerful antibiotic. BARDA's Project BioShield has exercised its first procurement option under a contract with Japanese drugmaker Shionogi, ordering $36.9 million worth of cefiderocol (brand name: Fetroja) to strengthen national preparedness against drug-resistant infections and potential biological threats.
Cefiderocol is no ordinary antibiotic — it's a siderophore cephalosporin that uses a novel mechanism to penetrate the tough outer membrane of gram-negative bacteria, bypassing the resistance defenses that render many other antibiotics useless. It's FDA-approved for complicated urinary tract infections and hospital-acquired or ventilator-associated bacterial pneumonia in adults, and has become a valued option for multidrug-resistant infections.
The contract, signed in April, is worth up to $482 million and includes plans to build a US manufacturing facility, expand cefiderocol's use in children with pneumonia, and study its potential against plague (Yersinia pestis) and melioidosis (Burkholderia pseudomallei) — two naturally occurring pathogens with bioweapon potential.
By the Numbers:
Why it matters: With antimicrobial resistance on the rise and bioterrorism threats ever-present, securing a stockpile of a novel, broad-spectrum antibiotic like cefiderocol is a critical step in protecting public health — both from everyday superbugs and worst-case biological attack scenarios.
